PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Kay, Jonathan
TI  - BOW-015 is Biosimilar to Infliximab with Respect to Efficacy and Safety
DP  - 2014 Aug 01
TA  - MD Conference Express
PG  - 17--18
VI  - 14
IP  - 17
4099  - http://mdc.sagepub.com/content/14/17/17.2.short
4100  - http://mdc.sagepub.com/content/14/17/17.2.full
AB  - Infliximab was the first anti—tumor necrosis factor a monoclonal antibody approved for the treatment of rheumatoid arthritis (RA). In 2013, CT-P13 was the first infliximab biosimilar agent approved by the European Commission. This Phase 3 trial of BOW-015 is the first study to compare an infliximab biosimilar agent with infliximab in patients with RA, assessing time points before Week 14.